Clinical application of new recombinant human granulocyte colony stimulating factor Efbemalenograstim α
Efbemalenograstim α is the third generation of new recombinant human granulocyte colony stimulating factor,which is a Class 1 new drug in China.It can increase the valley value of absolute count of neutrophil(ANC)and shorten the recovery time of ANC.For primary prevention of chemotherapy-induced neutrophil reduction.This article reviews its development,clinical studies,application conditions,adverse drug reactions and combination therapies in the stage of covid-19 infection with a view to providing reference for clinical use.
万方数据
维普
